Clinical trial NCT00381836 - References

Anemia — Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

Citation(s)

•   Aus G, Hugosson J, Norlén L
  Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995 Aug;154(2 Pt 1):460-5. Review.
•   Aus G, Hugosson J, Norlén L
  Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995 Aug;154(2 Pt 1):466-9.
•   Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A
  Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev. 2004;(3):CD003407. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD003407.
•   Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A
  Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005 Apr 6;97(7):489-98. Review.
•   Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A
  Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17;98(10):708-14. Review.
•   Borre M, Nerstrøm B, Overgaard J
  The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies. Acta Oncol. 1997;36(7):681-7.
•   Borre M, Nerstrøm B, Overgaard J
  The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer. 1997 Sep 1;80(5):917-28.
•   Brasso K, Friis S, Juel K, Jørgensen T, Iversen P
  The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. J Urol. 2000 Apr;163(4):1150-4.
•   Brasso K, Friis S, Kjaer SK, Iversen P
  [Prostatic cancer men under age 65. Occurrence and need for study]. Ugeskr Laeger. 1997 Apr 21;159(17):2543-5. Danish.
•   Carlsson P, Hjertberg H, Jönsson B, Varenhorst E
  The cost of prostatic cancer in a defined population. Scand J Urol Nephrol. 1989;23(2):93-6.
•   Dunn A, Carter J, Carter H
  Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manage. 2003 Dec;26(6):1132-9.
•   Egrie JC, Browne JK
  Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001 Apr;84 Suppl 1:3-10. Review.
•   Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB
  A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr;84 Suppl 1:17-23.
•   Heatherington AC, Schuller J, Mercer AJ
  Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer. 2001 Apr;84 Suppl 1:11-6.
•   Johansson JE, Wersäll P, Brandberg Y, Andersson SO, Nordström L; EPO-Study Group
  Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study. Scand J Urol Nephrol. 2001 Sep;35(4):288-94.
•   Ornstein DK, Beiser JA, Andriole GL
  Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int. 1999 Jan;83(1):43-6.
•   Otnes B, Harvei S, Fosså SD
  The burden of prostate cancer from diagnosis until death. Br J Urol. 1995 Nov;76(5):587-94.
•   Potosky AL, Miller BA, Albertsen PC, Kramer BS
  The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995 Feb 15;273(7):548-52.
•   Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J
  A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003 Jun 16;88(12):1851-8.
•   Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G
  Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997 Jun;79(6):933-41.
•   Varlotto J, Stevenson MA
  Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):25-36. Review.
•   Williams KJ, Parker CA, Stratford IJ
  Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? Adv Exp Med Biol. 2005;566:285-94. Review.

A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia

Details for clinical trial NCT00381836